Bayer, the agrochemical and biotech giant, has reached a significant settlement concerning its Roundup weed killer. On June 25, 2026, a judge in Missouri approved a settlement that could require Bayer to pay up to $7.25 billion to individuals claiming the product caused their cancer.
This settlement addresses claims from thousands diagnosed or to be diagnosed with non-Hodgkin lymphoma. They allege a link to glyphosate, Roundup’s active ingredient. Compensation ranges from $10,000 to $165,000 based on factors like occupational exposure and age at diagnosis.
Bayer’s CEO, Bill Anderson, described the agreement as a “decisive milestone” aimed at reducing legal risks. Judge Timothy Boyer highlighted its magnitude, calling it “one of the largest” in mass tort settlements.
Previously, the U.S. Supreme Court protected Bayer from certain lawsuits, supporting the company’s stance against warning labels for glyphosate. Despite EPA findings not linking glyphosate to cancer, it faces ongoing pressure to review health data.
Prominent scientists and the World Health Organization have linked glyphosate to cancer. Nevertheless, Bayer denies these claims, supported by the Trump administration’s actions, such as backing Bayer in the Supreme Court and encouraging domestic glyphosate production.
Despite removing glyphosate from U.S. residential products years ago, the chemical remains in agricultural use. This development aligns with other settlements, where Bayer agreed to pay up to $11 billion for similar claims. Christopher Seeger, attorney for plaintiffs, remarked on the justice delivered to victims after a decade-long wait.
